Cancer immunotherapy with semi-allogeneic cells

Details Cancer immunotherapy with semi-allogeneic cells Cancer immunotherapy with semi-allogeneic cells

2008-07-22

2008-07-22

Yaen, Christopher (Department: 1643)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

C435S325000

Reexamination Certificate

active

07402306

ABSTRACT:
The present invention relates to improved semi-allogeneic immunogenic cells which act to stimulate and induce an immunological response when administered to an individual. In particular, it relates to cells which express both allogeneic and syngeneic MHC determinants and which also express at least one antigen recognized by T lymphocytes. The invention is also directed to methods of inducing an immune response and methods of treating tumors by administering the semi-allogeneic immunogenic cells to an individual.

REFERENCES:
patent: 5674486 (1997-10-01), Sobol et al.
patent: 5750102 (1998-05-01), Eisenbach et al.
patent: 6022538 (2000-02-01), Santoli et al.
patent: 6228357 (2001-05-01), Maudsley
patent: 6277368 (2001-08-01), Hiserodt et al.
patent: 6805869 (2004-10-01), Guo
patent: 7060802 (2006-06-01), Trakht et al.
patent: 2002/0058041 (2002-05-01), Belldegrun et al.
patent: 2002/0085997 (2002-07-01), Schmidt et al.
patent: 0 569 678 (1993-11-01), None
patent: 0569678 (1993-11-01), None
patent: 9307906 (1993-04-01), None
patent: 9811202 (1998-03-01), None
patent: WO 98/11202 (1998-03-01), None
patent: WO 98/14205 (1998-04-01), None
Evans et al Quart. J. Med. vol. 92 pp. 299-307, 1999.
Lappin MB et al Blood Reviews 2000 14:228-239.
Roitt et al Immunology 4th ed. 1998 pp. 11.7-11.14.
Weiner L.M., Seminars Oncology, vol. 26, No. 4, Suppl 12, pp. 41-50, 1999.
Bellone et al. . (Immunology Today, v20 (10), 1999, pp. 457-462).
Gura (Science, v278, 1997, pp. 1041-1042).
Sun T. et al. Cancer Gene Therapy 2(3): 183-190, 1995.
D.L. Shawler et al. (1997) “Gene Therapy Approaches to Enhance Antitumor Immunity”Advances in Pharmacology 40:309-337.
T. Boon et al. (1992) “Identification of Tumor Rejection Antigens Recognized By T-Lymphocytes”Cancer Surveys 13: 23-37.
T. Boon (1993) “Tumor Antigens Recognized By Cytolytic T Lymphocytes: Present Perspectives for Specific Immunotherapy”Int. J. Cancer 54: 177-180.
T. Boon (1992) “Toward a Genetic Analysis of Tumor Rejection Antigens”Advances in Cancer Research 58: 177-209.
J. Vieweg and E. Gilboa (1995) “Considerations for the Use of Cytokine-Secreting Tumor Cell Preparations for Cancer Treatment”Cancer Investigation: 13 (2): 193-201.
K.M. Hui et al. (1989) “Tumor Rejection Mediated by Transfection With Allogeneic Class I Histocompatibility Gene”The Journal of Immunology 143(11): 3835-3843.
S. Ostrand-Rosenberg et al. (1991) “Tumor-Specific Immunity Can Be Enhanced By Transfection of Tumor Cells With Syngeneic MHC-Class-II Genes or Allogeneic MHC-Class-I Genes”Int. J. Cancer 6(Supp.): 61-68.
J.A. Roth and R.J. Cristiano (1997) “Gene Therapy for Cancer: What Have We Done and Where Are We Going?”Journal of the National Cancer Institute 89(1): 21-39.
T.S. Kim and E.P. Cohen (1994) “MHC Antigen Expression By Melanomas Recovered From Mice Treated With Allogeneic Mouse Fibroblasts Genetically Modified for Interleukin-2 Secretion and the Expression of Melanoma-associated Antigens”Cancer Immunol. Immunother.(1994) 38: 185-193.
T.S. Kim et al. (1992) “Immunity to B16 Melanoma in Mice Immunized With IL-2-secreting Allogeneic Mouse Fibroblasts Expressing Melanoma-associated Antigens”Int. J. Cancer 51:283-289.
E.P. Cohen and T.S. Kim (1994) “Neoplastic Cells That Express Low Levels of MHC Class I Determinants Escape Host Immunity”Seminars in Cancer Biology 5:419-428.
T. Itaya et al. (1987) “Xenogenization of a Mouse Lung Carcinoma (3LL) By Transfection With An Allogeneic Class I Major Histocompatibility Complex Gene (H-2Ld)1”Cancer Research 47: 3136-3140.
T. Lichtor et al. (1995) “Prolonged Survival of Mice With Glioma Injected Intracerebrally With Double Cytokine-secreting Cells”J. Neurosurg. 83: 1038-1044.
P. van der Bruggen et al. (1991) “A Gene Encoding an Antigen Recognized By Cytolytic T Lymphocytes on a Human Melanoma”Science 254: 1643-1647.
D.L. Toffaletti et al. (1983) “Augmentation of Syngeneic Tumor-specific Immunity By Semiallogeneic Cells Hybrids”The Journal of Immunology 130(6): 2982-2986.
M. I. Colnaghi (1975) “Histocompatibility Antigens Acting as Helper Determinants for Tumor-associated Antigens of Murine Lymphosarcoma”Eur. J. Immunol. 5: 241-245.
W. Xu et al. (1998) “Co-expression of Immunogenic Determinants by the Same Cellular Immunogen is Required for the Optimum Immunotherapeutic Benefit in Mice With Melanoma”Cancer Immunol. Immunother. 45: 217-224.
D.R. Wang et al. (1985) “Leukemia x Fibroblast Hybrid Cells Prolong the Lives of Leukemic Mice”Eur. J. Cancer Clin. Oncol. 21(5): 637-645.
W. Liang and E.P. Cohen (1976) “Resistance to Murine Leukemia in Mice Rejecting Syngeneic Somatic Hybrid Cells”The Journal of Immunology 116(3): 623-626.
W. Liang and E.P. Cohen (1977) “Activation of Specific Cellular Immunity Toward Murine Leukemia in Mice Rejecting Syngeneic Somatic Hybrid Cells”The Journal of Immunology 119(3): 1054-1060.
B.S. Kim et al. (1979) “Tumor-specific Immunity Induced by Somatic Hybrids”The Journal of Immunology 123(2): 733-738.
S.L. Garber et al. (1984) “Persistence of the Immunoprotective Effects of Leukemia x Fibroblast Hybrid Cells Toward Leukemia in Histocompatible Mice”Leukemia Research 8(2): 255-266.
R. Slomski et al. (1984) “Surface Antigens of Immunoprotective Leukaemia x Fibroblast Hybrid Cells Which Have Lost Malignant Properties in Histocompatible Mice Differ From the Malignant Parental Cells”Immunology 52:281-290.
W. Liang and E.P. Cohen (1977) “Resistance to Murine Leukemia in Mice Receiving Simultaneous Injections of Syngeneic Hybrid and Parental Neoplastic Cells”The Journal of Immunology 118(3): 903-908.
J. Jami and E. Ritz (1975) “Tumor-associated Transplantation Antigens in Immune Rejection of Mouse Malignant Cell Hybrids”Proc. Nat. Acad. Sci. USA 72(6): 2130-2134.
J. Jami and E. Ritz (1973) “Nonmalignancy of Hybrids Derived From Two Mouse Malignant Cells. I. Hybrids Between L1210 Leukemia Cells and Malignant L. Cells”Journal of the National Cancer Institute 51(5): 1647-1653.
S.E. Karp et al. (1993) “Cytokine Secretion By Genetically Modified Nonimmunogeneic Murine Fibrosarcoma Tumor Inhibition by IL-2 but Not Tumor Necrosis Factor”The Journal of Immunology 150(3): 896-908.
T.S. Kim et al. (1993) “Independent Cell Types Are Involved in the Induction of Antimelanoma Responses in C57BL/6 Mice Immunized with Interleukin-2-secreting Allogeneic Mouse Fibroblasts Expressing Melanoma-associated Antigens”Journal of Immunotherapy 14: 298-304.
T.S. Kim et al. (1993) “Immunization With Interleukin-2-secreting Allogeneic Mouse Fibroblasts Expressing Melanoma-associated Antigens Prolongs the Survival of Mice With Melanoma”Int. J. Cancer 55: 865-872.
D.M. Pardoll (1993) “Cancer Vaccines”Immunology Today 14(6): 310-316.
D. Pardoll (1992) “New Strategies for Active Immunotherapy With Genetically Engineered Tumor Cells”Current Opinion in Immunology 4: 619-623.
A. Porgador et al. (1993) “Antimetastatic Vaccination of Tumor-bearing Mice With Two Types of IFN-λ Gene-inserted Tumor Cells”The Journal of Immunology 150(4): 1458-1470.
A. Porgador et al. (1993) “Anti-metastatic Vaccination of Tumor-bearing Mice With IL-2-Gene-inserted Tumor Cells”Int. J. Cancer 53: 471-477.
A. Porgador et al. (1992) “Interleukin 6 Gene Transfection into Lewis Lung Carcinoma Tumor Cells Suppresses the Malignant Phenotype and Confers Immunotherapeutic Competence Against Parental Metastatic Cells”Cancer Research 52: 3679-3686.
S.A. Rosenberg (1992) “The Immunotherapy and Gene Therapy of Cancer”Journal of Clinical Oncology 10(2): 180-199.
S.J. Russell et al. (1991) “Decreased Tumorigenicity of a Transplantable Rat Sarcoma Following Transfer and Expression of a

Affiliated with

Also associated with

Rating

Cancer immunotherapy with semi-allogeneic cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer immunotherapy with semi-allogeneic cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer immunotherapy with semi-allogeneic cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2791697